A5103268153- Amyotrophic Lateral Sclerosis Research
- Chronic Lymphocytic Leukemia Research
- Neurogenetic and Muscular Disorders Research
- Acute Lymphoblastic Leukemia research
- Polyomavirus and related diseases
- Neuroinflammation and Neurodegeneration Mechanisms
- Cutaneous lymphoproliferative disorders research
- biodegradable polymer synthesis and properties
- Cancer-related gene regulation
- Multiple Sclerosis Research Studies
- Endometrial and Cervical Cancer Treatments
- Alzheimer's disease research and treatments
- Multiple Myeloma Research and Treatments
- Fungal Plant Pathogen Control
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Mycobacterium research and diagnosis
- Immune cells in cancer
- Viral-associated cancers and disorders
- Reproductive System and Pregnancy
- Rheumatoid Arthritis Research and Therapies
- Parkinson's Disease Mechanisms and Treatments
University College London
2021-2025
Hertfordshire Partnership University NHS Foundation Trust
2025
National Hospital for Neurology and Neurosurgery
2021-2024
Queen Mary University of London
2018-2024
State Hospital
2023
William Harvey Research Institute
2022
Barts Health NHS Trust
2019-2022
Royal London Hospital
2018-2022
University of Sheffield
2022
King's College London
2022
Abstract The routine clinical integration of individualized objective markers disease activity in those diagnosed with the neurodegenerative disorder amyotrophic lateral sclerosis is a key requirement for therapeutic development. A large, multicentre, clinic-based, longitudinal cohort was used to systematically appraise leading candidate biofluid biomarkers stratification and potential assessment sclerosis. Incident patients (n = 258), other neurological diseases 80) healthy control...
Amyotrophic lateral sclerosis (ALS) is a life-threatening disease characterised by progressive loss of motor neurons with few therapeutic options. The MIROCALS study tested the hypothesis that low-dose interleukin-2 (IL-2LD) improves survival and function in ALS. In this randomised, double-blind, placebo-controlled trial, male female riluzole-naive participants, either possible, laboratory-supported probable, or definite ALS diagnosis (revised El Escorial criteria), aged 18-76 years, symptom...
Aging is known to exacerbate neuroinflammation, and in the neurodegenerative disorder amyotrophic lateral sclerosis (ALS), an older age associated with a worse prognosis. We have previously shown activation of cell senescence pathways proteome peripheral blood mononuclear cells increase proinflammatory cytokines from individuals living ALS. In this single-center, retrospective study, we investigated expression senescent-like ALS.We first applied multidimensional cytometry by time-of-flight...
It is unclear to what extent pre-clinical studies in genetically homogeneous animal models of amyotrophic lateral sclerosis (ALS), an invariably fatal neurodegenerative disorder, can be informative human pathology. The disease modifying effects most therapeutic compounds have not been reproduced patients. To advance therapeutics ALS, we need easily accessible biomarkers which discriminate across the phenotypic variants observed ALS patients and bridge Peripheral blood mononuclear cells...
Monocytes expressing the inflammation suppressing active CD11b, a beta2 integrin, may regulate neuroinflammation and modify clinical outcomes in amyotrophic lateral sclerosis (ALS). In this single site, retrospective study, peripheral blood mononuclear cells from 38 individuals living with ALS 20 non-neurological controls (NNC) were investigated using flow cytometry to study CD11b integrin classical (CM), intermediate (IM) non-classical (NCM) monocytes during progression. Seventeen...
Abstract Objective To appraise the utility as biomarkers of blood antibodies and immune complexes to neurofilaments dipeptide repeat proteins, products translation most common genetic mutation in amyotrophic lateral sclerosis (ALS). Methods Antibodies against neurofilament light, medium, heavy chains well poly‐(GP)‐(GR) repeats were measured samples from ALS Biomarkers ( n = 107) phenotype–genotype biomarker 129) studies 140 healthy controls. Target analyte levels studied longitudinally 37...
A considerable number of people with multiple sclerosis (pwMS) live in low- and middle-income countries (LMIC), where lack resource adversely affects access to effective disease-modifying treatment.The objective this commentary is propose a useful cost-effective treatment option for pwMS LMIC potential high efficacy convenience the treating physician.Viewpoint: We using generic 2-chloro-2'-deoxyadenosine (cladribine), small molecule licensed hairy cell leukaemia, as solution significant...
Abstract Objective To test antibody response and formation of immune-complexes to neurofilaments dipeptide-repeats, the translational products mutated C9orf72 gene, as potential biomarkers for clinical stratification amyotrophic lateral sclerosis (ALS). Methods Using neurofilament protein isoforms plasma expression reference, antibodies against neurofilament-light, medium heavy chain poly-(GP)-GR dipeptide-repeats were tested in blood from 105 fast slow progressing ALS patients, 26 mutation...
Abstract Neuroinflammation impacts on the progression of amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disorder. Specialized pro-resolving mediators trigger resolution inflammation. We investigate specialized mediator blood profile and their receptors’ expression in peripheral mononuclear cells relation to survival ALS. People living with ALS (pwALS) were stratified based bulbar versus limb onset key metrics using latent class model, separate faster progressing from slower...
To address a critical issue - severe treatment-induced lymphopenia during the European Medicines Agency (EMA)-assessment of cladribine, highly effective disease modifying treatment (DMT) for people with multiple sclerosis (pwMS).
Objective To examine the association between socioeconomic status (SES) and prescription of disease-modifying treatments (DMTs) in people with multiple sclerosis (pwMS). Methods A cross-sectional study was conducted among 734 pwMS aged ≥18 years attending neuroinflammation service at The Royal London Hospital (Barts Health NHS Trust) 1997 2017. SES determined by patient income education extracted from English Index Multiple Deprivation. Multinomial logistic regression performed to assess...
To describe two cases of severe skin reactions in patients receiving Cladribine to control their multiple sclerosis (MS).
To evaluate the contribution of PAX2, ARID1A, and FOXA1 biomarkers to diagnosis in cases with atypical endometrial hyperplasia (AEH).Descriptive Study. Place Duration Study: Pathology Department Umraniye Training Research Hospital, from January 2018 December 2020.Curettage materials 100 patients diagnosed AEH which stained FOXA1, were evaluated. The staining patterns glandular areas grouped as slight-no loss, moderate complete loss / severe for all three biomarkers. Complete or/severe was...
Introduction Cladribine tablets (Mavenclad®) are licensed for treating people with relapsing multiple sclerosis (pwRMS). We treated (pwRMS) and progressive MS (pwPMS) using sub- cutaneously administered cladribine (SCAC) since 2014. Here, we present up to five year follow-up on safety efficacy. Methods SCAC 10mg was given 3–4 days during week 1. 0–3 doses were at 5, according 4 lymphocyte count. A second cycle of 11 months later. Follow-up included clinical outcome evaluation...